Cheshire-Based Biotech Scores £30m Series A Round

Why It Matters

The infusion of £30 million strengthens the scarce pipeline of new antibiotics, addressing a global health threat from resistant Gram‑negative bacteria. Successful progression of CTX‑187 could provide a novel therapeutic option and attract further investment into antimicrobial innovation.

Key Takeaways

• £30m Series A raised for antimicrobial pipeline.
• £6m contributed by AMR Action Fund.
• CTX-187 targets drug‑resistant Gram‑negative bacteria.
• Funding moves CTX‑187 toward Phase II readiness.
• Centauri previously secured £3.8m from CARB‑X accelerator.

Pulse Analysis

Antimicrobial resistance remains one of the most pressing challenges for global health systems, with Gram‑negative bacteria accounting for a growing share of untreatable infections. Traditional antibiotic pipelines have stalled, prompting governments and venture funds to allocate capital toward novel approaches. The AMR Action Fund’s £6 million stake in Centauri underscores a broader shift toward targeted financing for breakthrough antimicrobial therapies, signaling confidence that private capital can help close the drug‑development gap.

Centauri’s lead candidate, CTX‑187, leverages the company’s Alphamer platform, an immunotherapy strategy designed to enhance the body’s innate defenses against resistant pathogens. By focusing on a non‑traditional mechanism—modulating immune response rather than directly killing bacteria—the programme aims to reduce the selective pressure that drives resistance. The recent Series A round will fund the completion of Phase I trials, a critical milestone that will generate safety and pharmacokinetic data needed to design robust Phase II studies and attract downstream partners.

The £30 million raise not only propels Centauri’s pipeline but also reinforces the UK’s reputation as a hub for biotech innovation. Successful advancement of CTX‑187 could catalyze further investment in the region, encouraging other start‑ups to pursue immunotherapeutic solutions for infectious disease. For investors, the deal illustrates a growing appetite for high‑impact, high‑need therapeutics, while for the healthcare market it promises a potential new class of treatments that could alleviate the looming crisis of antibiotic resistance.